Inmaculada Rioja

2.3k total citations
39 papers, 1.1k citations indexed

About

Inmaculada Rioja is a scholar working on Molecular Biology, Hematology and Immunology. According to data from OpenAlex, Inmaculada Rioja has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 10 papers in Hematology and 7 papers in Immunology. Recurrent topics in Inmaculada Rioja's work include Protein Degradation and Inhibitors (22 papers), Multiple Myeloma Research and Treatments (9 papers) and Histone Deacetylase Inhibitors Research (7 papers). Inmaculada Rioja is often cited by papers focused on Protein Degradation and Inhibitors (22 papers), Multiple Myeloma Research and Treatments (9 papers) and Histone Deacetylase Inhibitors Research (7 papers). Inmaculada Rioja collaborates with scholars based in United Kingdom, United States and Germany. Inmaculada Rioja's co-authors include Rab K. Prinjha, Marion C. Dickson, Alexander Tarakhovsky, Michael Binks, Chun‐wa Chung, Catriona Sharp, David F. Tough, Uwe Schaefer, María Carmen Terencio and Amalia Úbeda and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and The Journal of Experimental Medicine.

In The Last Decade

Inmaculada Rioja

38 papers receiving 1.1k citations

Peers

Countries citing papers authored by Inmaculada Rioja

Since Specialization

Citations

This map shows the geographic impact of Inmaculada Rioja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inmaculada Rioja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inmaculada Rioja more than expected).

Fields of papers citing papers by Inmaculada Rioja

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inmaculada Rioja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inmaculada Rioja. The network helps show where Inmaculada Rioja may publish in the future.

Co-authorship network of co-authors of Inmaculada Rioja

This figure shows the co-authorship network connecting the top 25 collaborators of Inmaculada Rioja. A scholar is included among the top collaborators of Inmaculada Rioja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inmaculada Rioja. Inmaculada Rioja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NLRP3 inflammasome–driven hemophagocytic lymphohistiocytosis occurs independent of IL-1β and IL-18 and is targetable by BET inhibitors 2025 ·Science Advances ·(unknown), (unknown), (unknown), Xiuquan Ma, James Rickard, (unknown), Catherine N. Hall, Andrew J. Kueh, Seth L. Masters, Inmaculada Rioja, Rab K. Prinjha, Marcel Doerflinger, Kate E. Lawlor, Maryam Rashidi, James E. Vince	0
2	Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe 2023 ·Journal of Medicinal Chemistry ·Erin K. Bradley, (unknown), Chun‐wa Chung, Peter D. Craggs, Emmanuel H. Demont, P. G. Humphreys, Darren J. Mitchell, (unknown), Inmaculada Rioja, (unknown), Christopher R. Wellaway, Rab K. Prinjha, David Scott Palmer, William J. Kerr, Marc Reid, Ian D. Wall, (unknown)	6
3	In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer 2023 ·British Journal of Cancer ·(unknown), David W. James, (unknown), (unknown), Lavinia Margarit, Nagindra Das, (unknown), (unknown), Inmaculada Rioja, Rab K. Prinjha, Nicola Harker, Deyarina González, R. Steven Conlan, Lewis W. Francis	2
4	Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells 2023 ·Clinical Epigenetics ·(unknown), David W. James, (unknown), Lydia C. Powell, (unknown), (unknown), (unknown), Neil Garton, Nagindra Das, (unknown), Lavinia Margarit, (unknown), Inmaculada Rioja, Rab K. Prinjha, Nicola Harker, Deyarina González, R. Steven Conlan, Lewis W. Francis	4
5	Cohesin couples transcriptional bursting probabilities of inducible enhancers and promoters 2022 ·Nature Communications ·(unknown), Sergi Cuartero, Adrià Cañellas‐Socias, Sarah Wells, Mohammad M. Karimi, Elisabetta Mereu, Alexandra G. Chivu, Holger Heyn, Chad Whilding, Dirk Dormann, Samuel Marguerat, Inmaculada Rioja, Rab K. Prinjha, Michael P. H. Stumpf, Amanda G. Fisher, Matthias Merkenschlager	20
6	A BET Protein Inhibitor Targeting Mononuclear Myeloid Cells Affects Specific Inflammatory Mediators and Pathways in Crohn’s Disease 2022 ·Cells ·(unknown), (unknown), (unknown), Jan Verhoeff, Andrew Y. F. Li Yim, V Joustra, (unknown), Ivan Ting Hin Fung, Inmaculada Rioja, Rab K. Prinjha, Nicholas Smithers, Rebecca C. Furze, Palwinder K. Mander, Matthew Bell, Christianne J. Buskens, Geert D’Haens, Manon E. Wildenberg, Wouter J. de Jonge	4
7	Essential Bromodomain Tc BDF2 as a Drug Target against Chagas Disease 2022 ·ACS Infectious Diseases ·(unknown), (unknown), Victoria Lucía Alonso, (unknown), (unknown), Rab K. Prinjha, (unknown), Inmaculada Rioja, Roberto Docampo, Félix Calderón, Julio Martín, Esteban Serra	9
8	IFN-γ Drives Human Monocyte Differentiation into Highly Proinflammatory Macrophages That Resemble a Phenotype Relevant to Psoriasis 2021 ·The Journal of Immunology ·(unknown), (unknown), Mathias Kalxdorf, (unknown), William L. Thompson, H. Christian Eberl, (unknown), Johannes Freudenberg, Catriona Sharp, Jan Van den Bossche, Wouter J. de Jonge, Inmaculada Rioja, Rab K. Prinjha, Annette E. Neele, Menno P.J. de Winther, Palwinder K. Mander	32
9	Signaling function of PRC2 is essential for TCR-driven T cell responses 2018 ·The Journal of Experimental Medicine ·Marc‐Werner Dobenecker, Joon Seok Park, (unknown), Michael T. McCabe, Richard Gregory, Steven D. Knight, Inmaculada Rioja, Anna K. Bassil, Rab K. Prinjha, Alexander Tarakhovsky	38
10	BET Inhibition Improves NASH and Liver Fibrosis 2018 ·Scientific Reports ·Sarah Middleton, (unknown), Leanne Cutler, Palwinder K. Mander, Inmaculada Rioja, Rab K. Prinjha, Deepak K. Rajpal, Pankaj Agarwal, Vinod Kumar	29
11	BET bromodomain inhibition reduces maturation and enhances tolerogenic properties of human and mouse dendritic cells 2016 ·Molecular Immunology ·Ronald Schilderink, Matthew Bell, (unknown), (unknown), Inmaculada Rioja, Francisca W. Hilbers, Pawel A. Kabala, Kris A. Reedquist, David F. Tough, Paul P. Tak, Rab K. Prinjha, Wouter J. de Jonge	23
12	BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells 2016 ·Stem Cell Research ·Jingjun Li, Jing Ma, Guofeng Meng, Hong Lin, (unknown), Jamie Wang, Jie Luo, Xiaohong Xu, David F. Tough, Matthew Lindon, Inmaculada Rioja, Jing Zhao, Hongkang Mei, Rab K. Prinjha, Zhong Zhong	30
13	Bromodomain Proteins Contribute to Maintenance of Bloodstream Form Stage Identity in the African Trypanosome 2015 ·PLoS Biology ·Danae Schulz, Monica R. Mugnier, (unknown), Hee Sook Kim, (unknown), David F. Tough, Inmaculada Rioja, Rab K. Prinjha, F. Nina Papavasiliou, Erik Debler	51
14	Histone H3 lysine 9 di-methylation as an epigenetic signature of the interferon response 2012 ·The Journal of Experimental Medicine ·Terry Fang, Uwe Schaefer, Ingrid Mecklenbräuker, (unknown), Scott Dewell, (unknown), Inmaculada Rioja, Valentino Parravicini, Rab K. Prinjha, Rohit Chandwani, Margaret R. MacDonald, Kevin Lee, Charles M. Rice, Alexander Tarakhovsky	132
15	Quantitative Power Doppler Ultrasonography Is a Sensitive Measure of Metacarpophalangeal Joint Synovial Vascularity in Rheumatoid Arthritis and Declines Significantly Following a 2-week Course of Oral Low-dose Corticosteroids 2010 ·The Journal of Rheumatology ·Maggie Larché, (unknown), Adrian Lim, Robert J. Eckersley, Frank Pétavy, Flaminia Chiesa, Inmaculada Rioja, Pauline T. Lukey, Michael Binks, C McClinton, (unknown), Peter C. Taylor	25
16	Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony‐stimulating factor 2008 ·Arthritis & Rheumatism ·Inmaculada Rioja, (unknown), Catriona Sharp, (unknown), (unknown), Mohammed Akil, Anthony G. Wilson, Michael Binks, Marion C. Dickson	111
17	Gene expression profiles in the rat streptococcal cell wall-induced arthritis model identified using microarray analysis 2004 ·Arthritis Research & Therapy ·Inmaculada Rioja, Chris L. Clayton, Simon J. Graham, Paul Life, Marion C. Dickson	26
18	A pyrroloquinazoline derivative with anti-inflammatory and analgesic activity by dual inhibition of cyclo-oxygenase-2 and 5-lipoxygenase 2002 ·European Journal of Pharmacology ·Inmaculada Rioja, María Carmen Terencio, Amalia Úbeda, Pedro Molina, Alberto Tárraga, (unknown), María José Alcaraz	22
19	A new ditriazine inhibitor of NF-κB modulates chronic inflammation and angiogenesis 2002 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Inmaculada Rioja, María Carmen Terencio, Amalia Úbeda, Ricardo Riguera, José Carlos Quintela, (unknown)	6
20	An anti-inflammatory ditriazine inhibiting leukocyte functions and expression of inducible nitric oxide synthase and cyclo-oxygenase-2 2000 ·European Journal of Pharmacology ·Inmaculada Rioja, Amalia Úbeda, María Carmen Terencio, Isabel Guillén, Ricardo Riguera, José M. Quintela, Carlos Peinador, (unknown), María José Alcaraz	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact